Imran Nathani, MD
Internal Medicine · Tomball, TXNPI 1164495339
Payments from drug & device makers
Across 171 payments — averaging $41.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$4K
- Astellas Pharma US Inc$403
- Amarin Pharma, Inc.$305
- Johnson & Johnson$296
- AstraZeneca$248
- AbbVie$202
- plus $2K from 33 others
What the payments were for
- Consulting fees$3,44349%
- Food & beverage$3,20745%
- Education$3996%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 27 | $3,917 |
| Astellas Pharma US Inc | 5 | $403 |
| Amarin Pharma, Inc. | 15 | $305 |
| Johnson & Johnson | 14 | $296 |
| AstraZeneca | 14 | $248 |
| AbbVie(2 entities) | 12 | $202 |
| Lilly USA, LLC | 10 | $179 |
| E.r. Squibb & Sons, L.L.C. | 3 | $160 |
| Amgen | 8 | $141 |
| Dexcom, Inc. | 7 | $129 |
| Bayer | 5 | $80 |
| Abbott | 5 | $79 |
| Radius Health, Inc. | 2 | $68 |
| Biosense Webster, Inc. | 1 | $68 |
| GSK | 3 | $67 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
| Merck | 4 | $54 |
| Pfizer | 3 | $49 |
| Esperion Therapeutics, Inc. | 2 | $48 |
| Eisai Inc. | 2 | $45 |
| Mylan Specialty L.p. | 2 | $44 |
| Sanofi-aventis U.S. LLC | 3 | $36 |
| Sanofi Pasteur Inc. | 2 | $32 |
| Abiomed | 1 | $31 |
| Philips North America LLC | 2 | $29 |
| Inspire Medical Systems, Inc. | 1 | $29 |
| Genentech USA, Inc. | 2 | $26 |
| Seqirus USA Inc | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 2 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Nevro Corp. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Corcept Therapeutics | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Exact Sciences | 1 | $15 |
| Novartis | 1 | $15 |
| Medtronic | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,048 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 71 | $65,153 |
| JanuviaSitagliptin Phosphate | 59 | $64,142 |
| OzempicSemaglutide | 57 | $61,494 |
| FarxigaDapagliflozin Propanediol | 42 | $41,527 |
| JardianceEmpagliflozin | 33 | $39,087 |
| EntrestoSacubitril/Valsartan | 37 | $34,812 |
| TrulicityDulaglutide | 12 | $20,168 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $19,566 |
| XareltoRivaroxaban | 16 | $17,223 |
| GemtesaVibegron | 11 | $12,199 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $10,266 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $5,675 |
| Atorvastatin Calcium | 518 | $4,807 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 97 | $3,293 |
| Gabapentin | 183 | $3,062 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $49 | $65,15371 claims |
| MerckJanuvia | $54 | $64,14259 claims |
| Novo NordiskOzempic | $3,917 | $61,49457 claims |
| AstraZenecaFarxiga | $248 | $41,52742 claims |
| NovartisEntresto | $15 | $34,81237 claims |
| Lilly USA, LLCTrulicity | $179 | $20,16812 claims |
| GSKTrelegy Ellipta | $67 | $19,56618 claims |
| Johnson & JohnsonXarelto | $296 | $17,22316 claims |
| AbbVieSynthroid | $202 | $1,24614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Tomball
- Muhammad IrfanTomball$30.6M
- Shamaila AslamTomball$7.5M
- Rajasekaran AnnamalaiTomball$5.7M
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.